secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2023-10-17T23:59:59+00:00
Accession:  0001558370-23-016473
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema appoints Scott Garland to Board; brings commercial expertise for late-stage palazestrant development
--------------------------------------------------------------------------------

- Scott Garland appointed to Board as Class III director effective Oct 16, 2023; term through 2026 annual meeting.
- Received initial equity: options for 21,520 shares (3-year vest) and 14,347 shares (vests by 2024 annual meeting).
- Annual cash retainer $40,000 plus $6,000 for Compensation Committee service; standard indemnification agreement.
- Garland formerly CEO of Portola (led Andexxa launch and Alexion acquisition) and held senior roles at Exelixis, Genentech, Amgen.
- Company highlights his commercial leadership as palazestrant advances to Phase 3 for breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023016473/0001558370-23-016473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023016473/olma-20231013x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer